Tugay, D. Et Al. 2023. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey. JOURNAL OF MEDICAL ECONOMICS , vol.26, no.1 , 720-730.

Tugay, D., TOP, M., AYDIN, Ö., BAVBEK, S., DAMADOĞLU, E., ÖNER ERKEKOL, F., ... Kalkan, I. K.(2023). Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey. JOURNAL OF MEDICAL ECONOMICS , vol.26, no.1, 720-730.

Tugay, Deniz Et Al. "Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey," JOURNAL OF MEDICAL ECONOMICS , vol.26, no.1, 720-730, 2023

Tugay, Deniz Et Al. "Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey." JOURNAL OF MEDICAL ECONOMICS , vol.26, no.1, pp.720-730, 2023

Tugay, D. Et Al. (2023) . "Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey." JOURNAL OF MEDICAL ECONOMICS , vol.26, no.1, pp.720-730.

@article{article, author={Deniz Tugay Et Al. }, title={Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey}, journal={JOURNAL OF MEDICAL ECONOMICS}, year=2023, pages={720-730} }